17β-{[(1,1-dimethylethyl)dimethylsilyl]oxy}-3-methoxyestra-1(10),2,4-trien-6-one | 307299-25-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17β-{[(1,1-dimethylethyl)dimethylsilyl]oxy}-3-methoxyestra-1(10),2,4-trien-6-one
• 英文别名: (17β)-17-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-methoxyestra-1,3,5(10)-trien-6-one；17β-(t-butyldimethylsiloxy)-3-methoxyestra-1,3,5(10)-trien-6-one；17beta-(t-Butyldimethylsiloxy)-3-methoxyestra-1,3,5(10)-trien-6-one；(8R,9S,13S,14S,17S)-17-[tert-butyl(dimethyl)silyl]oxy-3-methoxy-13-methyl-8,9,11,12,14,15,16,17-octahydro-7H-cyclopenta[a]phenanthren-6-one
• CAS: 307299-25-8
• 化学式: C₂₅H₃₈O₃Si
• 分子量: 414.66
• InChiKey: AFZBSQIFSZCWFY-CWWQDXLCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.58
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  17β-{[(1,1-dimethylethyl)dimethylsilyl]oxy}-3-methoxyestra-1(10),2,4-trien-6-one 在 咪唑 、 盐酸 、 N-氯代丁二酰亚胺 、 lithium aluminium tetrahydride 、 Amberlyst 15 、 四丙基高钌酸铵 、 potassium tert-butylate 、 水 、 对甲苯磺酸 、 N-甲基吗啉氧化物 、 原甲酸三乙酯 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 反应 52.5h， 生成 3-methoxy-7-methylestra-1,3,5(10),6-tetraen-17-one cyclic 1,2-ethanediyl acetal
  参考文献：
  名称：

  Synthesis of (3α,7β,17α)-7-methyl-19-norpregn-5(10)-en-20-yne-3,7,17-triol, a metabolite of ORG OD14, and its 7-epimer

  摘要：

  The syntheses of the 7beta-hydroxy metabolite of ORG OD14 (Livial((R))), (3alpha,7beta,17alpha)-7-methyl-19-norpregn-5(10)-en-20-yne-3,7,17-triol (35), and its 7-epimer, (3alpha,7alpha,17alpha)-7-methyl-19-norpregn-5(10)-en-20-yne-3,7,17-triol (11), are described.

  DOI：

  10.1016/s0039-128x(00)00233-6
• 作为产物：
  描述：

  19-nortestosterone 在 咪唑 、 氧气 、 sodium acetate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 17β-{[(1,1-dimethylethyl)dimethylsilyl]oxy}-3-methoxyestra-1(10),2,4-trien-6-one
  参考文献：
  名称：

  Synthesis of (3α,7β,17α)-7-methyl-19-norpregn-5(10)-en-20-yne-3,7,17-triol, a metabolite of ORG OD14, and its 7-epimer

  摘要：

  The syntheses of the 7beta-hydroxy metabolite of ORG OD14 (Livial((R))), (3alpha,7beta,17alpha)-7-methyl-19-norpregn-5(10)-en-20-yne-3,7,17-triol (35), and its 7-epimer, (3alpha,7alpha,17alpha)-7-methyl-19-norpregn-5(10)-en-20-yne-3,7,17-triol (11), are described.

  DOI：

  10.1016/s0039-128x(00)00233-6

文献信息

• Compounds with hydroxycarbonyl-halogenoalkyl side chain
  申请人：——

  公开号：US20030114524A1

  公开（公告）日：2003-06-19

  The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): 1 in which R 1 represents a hydrogen atom, etc., R 2 represents a C 1 -C 7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

  本发明提供了一种化合物，包括一个与所述基团化学键合的基团和一个含有口服后活性较低的化合物或其母体骨架的基团的部分，其中所述基团具有以下一般式（1）：其中R1代表氢原子，等，R2代表C1-C7卤代烷基基团，等，m代表2至14的整数，n代表2至7的整数，或该化合物的对映体，或该化合物的水合物或药用可接受盐，或其对映体。上述化合物在药用上具有优势，因为一般式（1）的基团使得类似抗雌激素的化合物附着在化合物的母体骨架上口服后显示出显著增加的活性。
• Compounds with hydroxycarbonyl-halogenoalkyl side chains
  申请人：Jo JaeChon

  公开号：US20050192449A1

  公开（公告）日：2005-09-01

  The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R 1 represents a hydrogen atom, etc., R 2 represents a C 1 -C 7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

  本发明提供了一种化合物，该化合物由一个基团和与该基团化学键合的基团组成，其中该基团包含一种在口服后具有低活性的化合物或其母体支架，而该基团具有以下一般式（1）：其中R1代表氢原子等，R2代表C1-C7卤代烷基等，m表示2到14的整数，n表示2到7的整数，或该化合物的对映体，或其水合物或药学上可接受的盐。上述化合物在药学上的使用中具有优点，因为一般式（1）的基团使得诸如抗雌激素类化合物等连接到化合物的母体支架上后，在口服后能够显著增加其活性。
• Newly discovered orally active pure antiestrogens
  作者：Yoshitake Kanbe、Myung-Hwa Kim、Masahiro Nishimoto、Yoshihito Ohtake、Takaaki Yoneya、Iwao Ohizumi、Toshiaki Tsunenari、Kenji Taniguchi、Shin-ichi Kaiho、Yoshiaki Nabuchi、Hiroshi Araya、Setsu Kawata、Kazumi Morikawa、Jae-Chon Jo、Hee-An Kwon、Hyun-Suk Lim、Hak-Yeop Kim

  DOI：10.1016/j.bmcl.2006.06.047

  日期：2006.9

  In order to develop orally active pure antiestrogens, we incorporated the carboxy-containing side chains into the 7 alpha-position of the steroid scaffold and found that 17-keto derivative CH4893237 (12b) functioned as a pure antiestrogen with its oral activity much superior to clinically used pure antiestrogen, ICI182,780. Results from the pharmacokinetic evaluation indicated that the potent antiestrogen activity at oral dosing in mice attributed to both improved absorption from the intestinal wall and metabolic stability in liver. (c) 2006 Elsevier Ltd. All rights reserved.